Loading…
QURE
uniQure N.V.
NASDAQ· Healthcare· Biotechnology
$48.72-1.69%
Key metrics
- Market cap
- $3.38B
- P/E
- —
- Forward P/E
- —
- P/B
- 10.4x
- Dividend yield
- —
- EPS
- -$3.99
- ROE
- -157.61%
- Profit margin
- 0.00%
- Revenue growth
- +11.00%
- Beta
- 0.94
- 52-week high
- $71.50
- 52-week low
- $8.73
History
How the company evolved, year by year. Revenue and debt come from the annual statements; dividends from the payments themselves, which reach further back.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
About the company
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
- 221
- Amsterdam, Netherlands
Company description provided by Yahoo Finance.